Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
AI Sentiment
Neutral
5/10
as of 02-09-2026 2:55pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 1.1B | IPO Year: | 2019 |
| Target Price: | $17.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $18.31 | Next Earning Date: | 03-05-2026 |
| Revenue: | $147,190,000 | Revenue Growth: | 460.30% |
| Revenue Growth (this year): | 221.87% | Revenue Growth (next year): | 80.37% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -225377000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
AI Sentiment
Neutral
5/10
See how PHAT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.